中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Issue 4
Apr.  2008
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2008  >  24(4): 278-280

国产熊去氧胆酸治疗原发性胆汁性肝硬化患者的随访

  • Published Date: 2008-04-20
    Abstract
  • Objective To observe the liver function changes of ursoderoxycholic acid made in China for patients with primary biliary cirrhosis.Methods Choose patients with primary biliary cirrhosis diagnosed by liver biopsy or AMAM2 positive, treated by ursodeoxycholic acids mades in China, 13-15mg·kg-1·day-1 oral administration.Check the liver function every three months.Results Serum concentration of alkaline phosphatase, γ-glutamylaminotranspeptidase, alanine and aspartate aminotransferases fall markedly since the third month from the use of UDCA made in China.Conclusion UDCA treatment is associated with a marked improvement in serum biochemical markers of cholestasis.

     

    • FullText(HTML)
    • References(23)
  • [1]Heathcote E J.Management of primary biliary cirrhosis.The Ameri-can Association for the Study of liver disease practice guidelines[J].Hepatology, 2000, 31 (4) ∶1005-1013.
    [2]Poupon RE, Bonnand AM, Chretien Y, et al.Ten-year survival inursodeoxycholic acid-treated patients with primary biliarycirrhosis[J].Hepatology, 1999, 29 (6) ∶1668-1671.
    [3]Lazaridis KN, Gores GJ, Lindor KD.Ursodeoxycholic acid mecha-nisms of action and clinical use in hepatobiliary disorders[J].J Hep-atol, 2001, 35 (1) ∶134-146.
    [4]Hagey LR, Crombie DL, Espinosa E, et al.Ursodeoxycholic acid inthe Ursidae:biliary bile acids of bears, pandas, and related carni-vores[J].J Lipid Res, 1993, 34 (11) ∶1911-17.
    [5]Angulo P, Batts KP, Therneau TM, et al.Long term ursodeoxychol-ic acid delays histological progression in primary biliary cirrhosis[J].Hepatology, 1999, 29 (2) ∶644-7.
    [6]Goulis J, Leandro G, Burroughs AK.Randomized controlled trials ofursodeoxycholic acid therapy for primary biliary cirrhosis:a meta-a-nalysis[J].Lancet, 1999, 354∶1053-60.
    [7]Papatheodoridis GV, Adziyannis ES, Deutsch M, et al.Ursodeo-xycholic acid for primary biliary cirrhosis:final results of a 12-year, prospective, randomized, controlled trial[J].Am J Gastroenterol, 2002, 97 (8) ∶2063-2070.
    [8]张福奎, 贾继东, 王宝恩, 等.45例原发性胆汁性肝硬化的临床特征[J].中华内科杂志, 2002, 41 (1) ∶163-167.
    [9]陈国凤, 马威, 李莉, 等.47例原发性胆汁性肝硬化的临床分析[J].肝脏, 2003, 8 (1) ∶38-39.
    [10]崔恩斌, 李征, 张忠兵.原发性胆汁性肝硬化21例临床分析[J].中国实用内科杂志, 2003, 23 (2) ∶116-117.
    [11]Poupon R, Chretien Y, Poupon RE, et al.Is ursodeoxycholic acidan effect treatment for primary biliary cirrhosis?[J].Lancet, 1987, 1 (8537) ∶834-6.
    [12]Batta AK, Arora R, Salen G, et al.Characterization of serum andurinary bile acids in patients with primary biliary cirrhosis by gas-liquid chromatography-mass spectrometry:effect of UDCAtreatment[J].Journal of Lipid research, 1989, 30 (1) ∶1953-1962.
    [13]Jazrawi RP, Caestecker JS, Goggin PM, et al.Kinetics of hepaticbile acid handling in cholestatic liver disease:elicit of ursodeoxychol-ic acid[J].Gastroenterology, 1994, 106 (1) ∶134-42.
    [14]Paumgartner G, Beuers U.Ursodeoxycholic acid in cholestatic liverdisease:mechanisms of action and therapeutic use revisited[J].Hep-atology, 2002, 36 (3) ∶525-531.
    [15]Faubion W, Guicciardi M, Miyoshi H, et al.Toxic bile salts in-duce rodent hepatocyte apoptosis via direct activation of Fas[J].JClin Invest, 1999, 103 (1) ∶137-145.
    [16]Benz C, Angermuller S, ToxU, et al.Effect of tauroursodeoxychol-ic acid on bile-acid-induced apoptosis and cytolysis in rat hepato-cytes[J].J Hepatol, 1998, 28 (1) ∶99-106.
    [17]Qiao L, Yacoub A, Studer E, et al.Inhibition of the MAPK andPI3K pathways enhances UCDA-induced apoptosis in primary ro-dent hepatocytes[J].Hepatology, 2002, 35 (3) ∶779-789.
    [18]Rodrigues CM, Steer CJ.The therapeutic effects of ursodeoxych-olic acid as an anti-apoptotic agent[J].Expert Opin InvestigDrugs.2001, 10 (7) ∶1243-53.
    [19]Setchell KDR, Rodrigues CMP, Clerici C, et al.Bile acid concen-trations in human and rat liver tissue and in hepatocyte nuclei[J].Gastroenterology, 1997, 112 (2) ∶226-35.
    [20]Guldotana S, Zimmer G, Immhol M, et al.Molecular aspects ofmembrance stabilization by ursodeoxycholate[J].Gastroenterology, 1993, 104 (6) ∶1736-44.
    [21]Alpini G, Baiochchi L, Glaser S, et al.Ursodeoxycholate and taur-oursodeoxycholate inhibit cholangiocyte growth and secretion of BDLrats through activation of PKC alpha[J].Hepatology, 2002, 35 (5) ∶1041-1052.
    [22]Christophe C, Fabrice C, Raoul P, et al.Primary biliary cirrhosis:Incidence and predictive factors of cirrhosis development in Ursodiol-treated patients[J].Gastroenterology, 2002, 122 (2) ∶652-658.
    [23]Poupon RE, Lindor KD, Pares A, et al.Combined analysis of theeffect of treatment with ursodeoxycholic acid on histologic progressionin primary biliary cirrhosis[J].J Hepatol, 2003, 39 (1) ∶12-16.
    • Relative Articles

  • Relative Articles

    [1]Xinyu CUI, Yanyan LI, Na ZHU, Yingying LIN, Xin LI. Efficacy of ursodeoxycholic acid in the prevention and treatment of COVID-19 in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2024, 40(3): 489-495. doi: 10.12449/JCH240309
    [2]Nan WANG, Rong HU, Shihui BIAN, Wei ZHONG, Pengfei ZHANG, Youwen TAN. Value of alkaline phosphatase level after ursodeoxycholic acid treatment for one month and baseline red blood cell distribution width in predicting the treatment response of primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2024, 40(3): 496-501. doi: 10.12449/JCH240310
    [3]Haifeng LIU, Simin ZHOU, Jiwen LI, Jiangpeng LIU, Bangmao WANG, Lu ZHOU. Effect of depression on response to ursodeoxycholic acid and the occurrence of liver cirrhosis in patients with primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2023, 39(12): 2817-2823. doi: 10.3969/j.issn.1001-5256.2023.12.011
    [4]Chinese Society of Hepatology. Guidelines on the diagnosis and management of primary biliary cholangitis (2021)[J]. Journal of Clinical Hepatology, 2022, 38(1): 35-41. doi: 10.3760/cma.j.cn112138-20211112-00794
    [5]Zhang YuGuo, Zhao SuXian, Li WenCong, Ren WeiGuang, Nan YueMin. Clinical effect of ursodeoxycholic acid combined with diammonium glycyrrhizinate in treatment of primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2019, 35(6): 1322-1325. doi: 10.3969/j.issn.1001-5256.2019.06.028
    [6]Wang Lu, Sun KeShuai, Han ZheYi, Guo ZhangCun, Jia Gui, Gao KeNa, Zhang YaWei, Han Ying. Clinical effect of fenofibrate combined with ursodeoxycholic acid in treatment of primary biliary cholangitis patients with poor response to ursodeoxycholic acid alone[J]. Journal of Clinical Hepatology, 2018, 34(11): 2368-2372. doi: 10.3969/j.issn.1001-5256.2018.11.020
    [7]Jin QianWen, Tu ChuanTao. Pharmacotherapy for primary biliary cholangitis: basic concepts and research advances[J]. Journal of Clinical Hepatology, 2017, 33(8): 1589-1594. doi: 10.3969/j.issn.1001-5256.2017.08.039
    [9]Du Ying, Fang Lei. Clinical efficacy of traditional Chinese medicine/herbal decoction combined with ursodeoxycholic acid for primary biliary cirrhosis:a meta-analysis[J]. Journal of Clinical Hepatology, 2015, 31(1): 68-73. doi: 10.3969/j.issn.1001-5256.2015.01.015
    [10]Zhu JiangYi, Han Ying. Research advances in primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(2): 163-164. doi: 10.3969/j.issn.1001-5256.2015.02.004
    [12]Qin Hua, Bai ShiShan. Advances in treatment of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2013, 29(9): 719-721. doi: 10.3969/j.issn.1001-5256.2013.09.023
    [13]Hu XingWu, Qi ChangJin, Zhou HongXing. Therapeutic efficacy of ursodeoxycholic acid for drug-induced liver disease[J]. Journal of Clinical Hepatology, 2012, 28(9): 695-696.
    [14]Zhao YanJuan, Sun ZheYing. The therapeutic effect of ursodeoxycholic acid capsules in patients with primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2010, 26(4): 432-433.
    [15]Qin Gang, Shi GuangFeng, Li Qian, Lu Qing, Chen Shu. Inhibitory effects of UDCA on porcine serum-induced rat liver fibrosis[J]. Journal of Clinical Hepatology, 2007, 23(4): 263-265.
    [17]Tang ShuZhen, Liu XiaoMing, You Hong, Zhang FuKui, Wang BaoEn, Jia JiDong. Autoimmune related clinical tests in diagnosis of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2006, 22(3): 191-192.
    [18]Tan YouWen, Wu JianCheng, Wu XueJun. Efficacy of ursodeoxycholic acid in the treatment of type Ⅰ autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2004, 20(5): 283-284.
    [19]He WenTao, Shi JianShi. Clinical analysis of primary bilary cirrhosis.[J]. Journal of Clinical Hepatology, 2001, 17(3): 180-181.
    • Supplements(0)
    • Cited By
  • Created with Highcharts 5.0.7Amount of accessChart context menuAbstract Views, HTML Views, PDF Downloads StatisticsAbstract ViewsHTML ViewsPDF Downloads2024-042024-052024-062024-072024-082024-092024-102024-112024-122025-012025-022025-0305101520
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 3.1 %FULLTEXT: 3.1 %META: 92.5 %META: 92.5 %PDF: 4.5 %PDF: 4.5 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 5.2 %其他: 5.2 %其他: 0.5 %其他: 0.5 %China: 0.2 %China: 0.2 %[]: 0.2 %[]: 0.2 %上海: 0.7 %上海: 0.7 %中卫: 0.5 %中卫: 0.5 %丽水: 0.2 %丽水: 0.2 %兰州: 0.2 %兰州: 0.2 %凉山: 0.2 %凉山: 0.2 %北京: 7.1 %北京: 7.1 %南宁: 0.9 %南宁: 0.9 %南昌: 0.5 %南昌: 0.5 %台州: 2.1 %台州: 2.1 %吉林: 0.5 %吉林: 0.5 %周口: 0.2 %周口: 0.2 %咸阳: 0.2 %咸阳: 0.2 %哥伦布: 0.7 %哥伦布: 0.7 %大兴安岭: 0.2 %大兴安岭: 0.2 %大理: 0.2 %大理: 0.2 %天津: 0.5 %天津: 0.5 %广州: 0.2 %广州: 0.2 %张家口: 1.7 %张家口: 1.7 %成都: 0.7 %成都: 0.7 %拉斯维加斯: 0.2 %拉斯维加斯: 0.2 %朝阳: 0.2 %朝阳: 0.2 %杭州: 2.1 %杭州: 2.1 %武汉: 0.2 %武汉: 0.2 %沈阳: 0.2 %沈阳: 0.2 %洛阳: 0.2 %洛阳: 0.2 %淮南: 0.2 %淮南: 0.2 %深圳: 0.5 %深圳: 0.5 %温州: 0.2 %温州: 0.2 %湖州: 1.2 %湖州: 1.2 %石家庄: 0.5 %石家庄: 0.5 %科隆: 0.2 %科隆: 0.2 %美国伊利诺斯芝加哥: 0.2 %美国伊利诺斯芝加哥: 0.2 %自贡: 0.2 %自贡: 0.2 %芒廷维尤: 35.8 %芒廷维尤: 35.8 %莫斯科: 0.2 %莫斯科: 0.2 %衢州: 1.4 %衢州: 1.4 %西宁: 28.5 %西宁: 28.5 %贵阳: 0.2 %贵阳: 0.2 %赣州: 0.2 %赣州: 0.2 %郑州: 0.2 %郑州: 0.2 %金华: 0.7 %金华: 0.7 %长春: 1.4 %长春: 1.4 %长沙: 0.5 %长沙: 0.5 %青岛: 0.2 %青岛: 0.2 %其他其他China[]上海中卫丽水兰州凉山北京南宁南昌台州吉林周口咸阳哥伦布大兴安岭大理天津广州张家口成都拉斯维加斯朝阳杭州武汉沈阳洛阳淮南深圳温州湖州石家庄科隆美国伊利诺斯芝加哥自贡芒廷维尤莫斯科衢州西宁贵阳赣州郑州金华长春长沙青岛

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (2467) PDF downloads(949) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2482]YesterdayPV[4685]TodayIP[2214]TodayPV[4334]Online[60]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return